MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells

Li, Ningwei; Yang, Lu; Wang, Hongjing; Yi, Tao; Jia, Xibiao; Chen, Cen; Xu, Pan

doi:10.1371/journal.pone.0128886

Cited by 77 publications

(65 citation statements)

References 30 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain miRs may improve chemotherapy sensitivity, whereas others may induce chemoresistance of cancer cells (24)(25)(26). In ovarian cancer, miR-130a and miR-374a were demonstrated to function as negative regulators of cisplatin resistance in A2780 cells (27), whereas miR-31 positively regulated cisplatin resistance in numerous ovarian cancer cells (28). In the present study, miR-20a was identified as a novel positive regulator for OVCAR3 cells cisplatin resistance and migration.…”

Section: Discussionsupporting

confidence: 47%

MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line

Liu

Han

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) have been reported to be associated with the development of numerous types of cancer. However, the function of miRs in human ovarian carcinoma chemoresistance remains largely undefined. In the present study, cell chemotherapy combined with a Cell Counting Kit-8 assay demonstrated that miR-20a performed important roles in ovarian cancer cells chemoresistance. Flow cytometry, cellular proliferation assays and Transwell assays results revealed that the proliferation and migration rates of OVCAR3/DDP cells were increased in comparison with parental cells. Western blot analysis results suggested that epithelial-mesenchymal transition (EMT) activated by miR-20a contributed to OVCAR3/DDP cell migration. The present study highlighted the importance of miR-20a in regulating the chemoresistant properties of OVCAR3 cells and promoting cisplatin-resistant cell migration by activating EMT. The results of present study may therefore provide novel insights into reversing the chemoresistance of ovarian cancer and improving its treatment.

show abstract

Section: Discussionsupporting

confidence: 47%

MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line

Liu

Han

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Bladder cancer (BC), one of the most prevalent carcinomas worldwide, has been identified as the fourth and tenth leading cause of cancer-related deaths in males and females, respectively (1). Despite many efforts have been made, the prognosis still remains unsatisfied.…”

Section: Introductionmentioning

confidence: 99%

lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27

Xue

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Long non-coding RNAs (lncRNAs) have been identified as critical regulators in tumorigenesis. In our present study, we measured the level of small nucleolar RNA host gene 5 (SNHG5) in bladder cancer (BC) tissues and cell lines, and the correlation of the level of SNHG5 with clinicopathological features and prognosis of BC patients was analyzed. Reverse transcription-quantitative polymerase chain reaction was performed to determine the level of SNHG5 in the BC tissues and cell lines. The Kaplan-Meier method was used to analyze the long-term survival outcomes. MTT and colony formation assays were applied to assess the influence of SNHG5 on cell proliferation ability. Flow cytometry was used to measure the function of SNHG5 on cell cycle and apoptosis rate. SNGH5 was found upregulated in BC tissues and cell lines and a high level of SNGH5 was correlated with a poor prognosis. Silencing SNHG5 inhibited the proliferation ability of BC cells and such a function was attributed to its influence on cells cycle and apoptosis. Our findings imply that SNHG5 was upregulated in BC tissues and played an important role in BC progression and may be a potential therapeutic target for BC patients.

show abstract

“…The present study revealed that multiple miRNAs participate in ovarian cancer drug-resistance, including miRNA-130a and miRNA-374a (14). miRNA-152 and miRNA-185 were demonstrated to be significantly downregulated in SKOV3/DDP and A2780/DDP cells (14). Previous studies have demonstrated that miRNA-21 is involved in drug resistance in multiple types of cancer, including gastric, breast and lung cancer, via regulation of PTEN (7,8,15).…”

Section: Discussionmentioning

confidence: 50%

“…Although platinum-based chemotherapy has improved the prognosis of ovarian cancer, drug-resistance remains the main obstacle to successful treatment. The present study revealed that multiple miRNAs participate in ovarian cancer drug-resistance, including miRNA-130a and miRNA-374a (14). miRNA-152 and miRNA-185 were demonstrated to be significantly downregulated in SKOV3/DDP and A2780/DDP cells (14).…”

Section: Discussionmentioning

confidence: 58%

miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN

Chen

Tian

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are small non-coding RNAs, 8-23 nucleotides in length, which regulate gene expression at the post-transcriptional level. The present study was performed to analyze the association between microRNA-21 and cisplatin resistance in epithelial ovarian cancer (EOC) SKOV3 and SKOV3/DDP cells. In this experiment, the resistance of SKOV3 and SKOV3/DDP cells to cisplatin was evaluated using the MTT assay. Reverse transcription-quantitative polymerase chain reaction analysis was used to assess miRNA-21 levels and phosphatase and tensin homolog (PTEN) mRNA levels. Western blotting was used to assess PTEN protein levels. miRNA-21 mimics or inhibitors were transfected into SKOV3 and SKOV3/DDP cells. Prior to transfection, higher expression levels of miRNA-21 were observed in SKOV3/DDP cells compared with SKOV3 cells. Following transfection with miRNA-21 mimics, SKOV3 cells demonstrated increased sensitivity to cisplatin compared with negative control cells. Following transfection with the miRNA-21 inhibitor, SKOV3/DDP cells demonstrated decreased sensitivity to cisplatin compared with negative control cells. Furthermore, PTEN mRNA expression levels in SKOV3 cells transfected with miRNA-21 mimics was significantly lower compared with negative control cells. These results suggested that miRNA-21 may regulate cisplatin resistance by negatively targeting PTEN in EOC. IntroductionEpithelial ovarian cancer (EOC) is one of the most common malignant gynecologic tumors. Debulking surgery followed by a combination of platinum and taxane based chemotherapy are widely used treatments for EOC at present. Although overall survival rates have increased slightly over the past 25 years, 5-year survival remains <50% (1). The high mortality rate of ovarian cancer is due to late-stage diagnosis and resistance to platinum-based chemotherapy. However, the mechanisms underlying cisplatin resistance in EOC remain to be fully understood.MicroRNAs (miRNAs) are small non-coding RNAs of 8-23 nucleotides that post-transcriptionally regulate gene expression. Multiple previous reports have indicated that dysregulation of miRNA target genes promotes drug resistance, and inhibition of miRNAs may reverse drug resistance (2,3). miRNA-21 is overexpressed in multiple types of cancer, and promotes the initiation of cancer, progression and drug-resistance (4-9). miRNA-21 impacts tumorigenesis by negatively regulating several targets. Phosphatase and tensin homolog (PTEN) is a tumor suppressor molecule. Inactivating mutations and deletions of the PTEN gene have been observed in multiple types of cancer. Notably, bioinformatics tools have demonstrated that the 3'-untranslated region of the PTEN gene harbors a putative binding site for miRNA-21 (10). miRNA-21 expression has been revealed to be markedly increased in ovarian cancer compared with benign ovarian tumor tissues (11). miRNA-21 expression was also demonstrated to be increased in drug-resistant ovarian cancer compared with drug-sensitive ovarian cancer serum. In the present study,...

show abstract

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells

Cited by 77 publications

References 30 publications

MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line

MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line

lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27

miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN

Contact Info

Product

Resources

About